The within-and between-run precisions were less than 15%, and accuracy was −12.33% to 9.76%. The method was proved to be accurate and specific, and it was applied to a urinary excretion study of triazolam in healthy Chinese volunteers.
Introduction
Triazolam [8-chloro-6 -(o-chlorophenyl)-1-methyl-4H-striazol-(4,3-α) (1, 4) benzodiazepine] is a benzodiazepine approved by the Food and Drug Administration in the U.S. and Europe. Triazolam is a hypnotic indicated for the shortterm management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings (1, 2) .
Absorption of triazolam from tablets is rapid and complete in adult subjects of all ages. Maximum serum concentrations in fasting individuals generally occur between 1 and 2 h after administration. Food did not affect total area under the serum concentration curve (AUC) Triazolam is widely reported to be abused and is alleged to be involved in date-rape cases (4) . Deaths involving triazolam have been reported by toxicologists from several countries (5, 6) . In order to improve the detection ability of abused drugs like triazolam and study its pharmacokinetics, a selective and sensitive analytical method is essential. Several methods have been reported for the analysis of triazolam in biological fluids, including gas chromatography (GC) (7), GC-mass spectrometry (MS) (8) , high-performance liquid chromatography (HPLC) (9,10), LC-MS (4, 11) , and an LC-MS-MS method that was developed in our laboratory (12) .
In this paper, the LC-MS-MS method that we developed has extended its application to a different biological matrix, urine, with full validation. Results indicated that same extraction method produced less matrix effect. This paper also demonstrated that this method is suitable for urine matrix application as compared to plasma matrix. To our knowledge, no previous study has reported simultaneous determination of triazolam and its metabolites in human urine by LC-MS-MS.
In the present study, a simple, rapid, accurate, and sensitive LC-MS-MS method was established to simultaneously determine triazolam and its two major metabolites, α-OHTRZ and 4-OHTRZ, in human urine. This method was further applied to a urinary excretion study in a group of healthy volunteers after oral administration of triazolam.
Experimental Chemicals and reagents
The standard of triazolam, α-OHTRZ were purchased from Cerillant (Round Rock, TX). 4-OHTRZ was purchased from Biomol (Plymouth Meeting, PA). Triazolam-d 4 was purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile (ACN) and methanol (MeOH), both HPLC grade, were obtained from Tedia (Fairfield, OH) and Merck KgaA (Darmstadt, Germany), respectively. All the other chemicals are analytical grade and commercial available. Drug-free human urine used in this study was obtained from healthy Chinese volunteers and stored at -80°C until the assay. β-Glucuronidase (Type IX from E. coli, 1 MU/mL) was obtained from Sigma (St. Louis, MO). Water was prepared using a Milli-Q water purification system (Millipore, Bedford, MA). The Oasis ® HLB (hydrophilic-lipophilic balance) extraction cartridges was purchased from Waters (Milford, MA).
HPLC conditions
The HPLC system consisted of a pump (Shimadzu LC-10ADVP, Kyoto, Japan) and an autosampler (Shimadzu SIL-10ADVP). Chromatographic separation was performed with a Thermo ® C 18 column (2.1 × 50-mm i.d., 3-µm particle size, ThermoFisher, Waltham, MA). A mobile phase consisting of acetonitrile/H 2 O/formic acid (35:65:0.2, v/v/v) was used. The flow rate was set at 0.25 mL/min, and the auto sampler was conditioned at 4°C. The run time was 4 min.
MS conditions
An Applied Biosystems-Sciex API 3000 (Foster City, CA) triple-quadrupole MS equipped with an electrospray ionization (ESI) interface was used to perform this study. Ionization was conducted in the positive mode. Ion source temperature was maintained at 425°C and ionspray was 5500V. High-purity nitrogen gas was used as collision-induced dis sociation (CAD) gas (setting 12), curtain gas (setting 12), and nebulizer gas (setting 11). Multiple reaction monitoring (MRM) mode was used for the quantification. .0 ng/mL) were prepared by spiking an appropriate amount of the standard solutions into blank urine from healthy, nonsmoking volunteers (total added volume less than 10% of the biological sample volume). Quality control (QC) samples were prepared from a pool of different sources of blank urine at lower limit of quantification (LLOQ), low, medium, and high concentrations, which were set at 0.5, 25, 40, and 90 ng/mL for triazolam and 4-OHTRZ and 5, 250, 400, and 900 ng/mL for α-OHTRZ and used in pre-study validation and during the urinary excretion studies.
Sample preparation
Urine samples were prepared by solid-phase extraction (SPE). The SPE protocol from our previous study was followed with some modification (12) . The samples were stored as 1 mL aliquots at -80°C; the aliquots were thawed at room temperature before analysis. Fifty microliters of 2 M ammonium acetate (pH 5.0), 13 µL of β-glucuronidase, and a 50-µL aliquot of 50 ng/mL internal standard solution were added to 500 µL of urine sample; the sample was then incubated in a water bath at 50°C for 30 min. SPE was conducted by using Oasis HLB extraction cartridges. The cartridges were conditioned sequentially with 1 mL of MeOH and twice with 1 mL of H 2 O, and 500 µL of urine sample was then loaded. The loaded cartridges were washed with 1 mL of MeOH/H 2 O/NH 4 OH (5:95:2, v/v/v) twice, and subsequently the analyte was eluted with 2% formic acid in MeOH. The elution was then evaporated to dryness under N 2 stream at 40°C, reconstituted with 100 µL of HPLC mobile phase, and vortex mixed for 30 s. Finally, the solution was transferred to the autosampler vials, and 10 µL was injected into LC-MS-MS system.
Method validation
The method validation assays were carried out based on the currently accepted U.S. Food and Drug Administration (FDA) bioanalytical method validation guidance (13) .
During pre-study validation, six validation runs were conducted on six separate days. Each validation run consisted of a set of the calibration standards at eight concentrations over the concentration range and QC samples at four concentrations (n = 6 at each concentration).
The results from QC samples in six runs were used to evaluate the accuracy and within-and between-run precision of the method. The linearity was confirmed by plotting the peak-area ratio of triazolam, 4-OHTRZ, and α-OHTRZ to the internal standard versus triazolam, 4-OHTRZ, and α-OHTRZ concentrations. The unknown sample concentrations were calculated from the equation y = ax + b, where y is the peakarea ratio, x is the drug concentration, and a and b are the slope and y-intercept of the calibration curve, respectively.
Selectivity was evaluated by comparing chromatograms of six different sources of blank urine to evaluate the impact of interfering peaks at the retention times at the LLOQ of the analytes.
Six different sources of blank urine were used to assess the matrix effect. The absolute and relative matrix effects were previously defined by Matuszewski et al. (14) . The absolute matrix effect was evaluated by comparing the peak areas of analytes added to extracted blank urine with those of extracted water. The RSD of the mean peak areas of analytes in the extracted blank urine indicated the relative matrix effect.
The extraction recovery of triazolam, 4-OHTRZ, and α-OHTRZ at two concentrations (6 and 90 ng/mL for triazolam and 4-OHTRZ and 60 and 900 ng/mL for α-OHTRZ) was determined by comparing the responses ratio of extracted urine standards with those of extracted blank urine spiked with corresponding concentrations. The response was defined as the peak area of analyte divided by the peak area of IS.
The stability of three analytes and IS in human urine under different temperature and timing conditions, as well as their stability in the working solutions, was evaluated. Samples were subjected to working solution stability, to autosampler stability, to freeze-and-thaw stability, and to long-term stability. All the stability studies were conducted at concentration level (6, 50, and 90 ng/mL for triazolam and 4-OHTRZ; 60, 500, and 900 ng/mL for α-OHTRZ) with three replicates for each. The working solution was prepared as described and kept at ambient temperature (25°C) for 4 h. The peak-area ratio of the analytes of interest to IS obtained from samples stored for 4 h was compared with the values of initial samples. The autosampler stability was determined by comparing the concentration of reinjection of QC samples stored in an autosampler for 12 h with that of the initially analyzed QC samples. The freeze-and-thaw stability was evaluated by analyzing the observed concentration of QC samples processed with three freeze-thaw cycles as compared with that of the initial sample. For long-term stability, QC samples were stored at -80°C for 30 days and then processed and analyzed. Longterm stability was evaluated by comparing the concentrations obtained with the initial values.
Application of analytical method to urinary excretion studies
The LC-MS-MS procedure method developed was used to investigate the urinary excretion of each analyte after an oral administration of a 0.25-mg triazolam tablet to six healthy Chinese male volunteers. The study protocol was approved by the Institutional Review Board (IRB) of Tri-Service General Hospital (Taipei, Taiwan). All the volunteers were signed informed consent prior to participating in this study. Six healthy volunteers, with a mean age (± standard deviation, SD) of 23.9 ± 1.0 years and mean weight of 67.2 ± 10.1 kg, were selected for the study. All six subjects fasted overnight before the treatment. A single dose of triazolam (Trialam ® 0.25 mg/tab) was administered orally by the subjects. Following administration, urine samples were collected in the following intervals: 0-1, 1-2, 2-4, 4-8, 8-12, and 12-24 h. The volume of each urine sample at room temperature was recorded, and samples were stored at -80°C until analysis.
Results and Discussion

Method development
The most intensive product ion was observed at m/z 308. fore, the precursor-to-product ion transitions m/z 343. Table I .
Selectivity
Representative chromatograms of drug-free urine are shown in Figure 1A . Chromatograms corresponding to urine samples spiked with triazolam (0.5 ng/mL), α-OHTRZ (5 ng/mL), and 4-OHTRZ (0.5 ng/mL) are shown in Figure 1C . The retention times were 2.44, 1.70, 1.73, and 2.41 min for triazolam, α-OHTRZ, 4-OHTRZ, and trazolam-d 4 , respectively. No significant interfering peaks due to endogenous compounds or reagent were observed at the retention times of the three analytes of interest and internal standard in the chromatogram of blank urine.
Extraction recovery and matrix effect
The extraction recoveries of triazolam in urine were 97.63 ± 2.48% for low (5 ng/mL) and 93.34 ± 3.59% for high (90 ng/mL) concentrations. The extraction recoveries of α-OHTRZ were 124.68 ± 7.75% for low (60 ng/mL) and 104.47 ± 2.62% for high (900 ng/mL) concen trations, and for 4-OHTRZ, they were 113.40 ± 4.04% for low (5 ng/mL) and 101.27 ± 2.85% for high (90 ng/mL) concentrations.
Ion suppression or enhancement may occur during the analyzing process due to co-eluting endogenous components from the sample matrix, especially when using LC-MS-MS method. The importance of including the evaluation of matrix effect in any LC-MS-MS method is outlined in an excellent paper by Matuszewski et al. (14) . Their data strongly emphasize the need to use a blank matrix from different sources/individuals instead of using one blank matrix pool to determine method precision and accuracy. Therefore all validation experiments in this assay were performed with matrixes obtained from different individuals. The absolute and relative matrix effects are shown in Table II . The results of absolute matrix effect indicated that no significant ion suppression or ion enhancement occurred for triazolam, α-OHTRZ, and 4-OHTRZ, for which the values were all less than 15%. The relative matrix effects were all less than 12%, which indicated the impact of matrix effect from various urine sources was consistent and limited.
Linearity and LLOQ
The standard calibration curves of triazolam and its two metabolites were linear over the concentration ranges of 0.5- Table II Results are expressed as mean ± SD (n = 6). Table  II . RE was within the acceptable range (±20%), and RSD was lower than 20%.
Accuracy and precision
The accuracy was determined by calculating the percentage deviation observed in the analysis of QC samples and expressed as the relative error (RE). Within-and between-run precision were expressed as the relative standard deviation (RSD). The data of accuracy and precision are shown in Table III , as the results showed, the precisions (RSD) and accuracies (RE) of QC samples for within-and between-run precision were all in the acceptable range (RSD < 15% and RE within ±15%), which indicated the analytical method was precise and accurate within the analytical range.
Stability
The data are shown in Table IV . Working solution, autosampler, freeze and thaw, and long-term stability tests were all evaluated by the RE. Triazolam and its two metabolites showed ideal stability for all the tests. The results indicated that this analytical method was proved to be applicable for routine analysis.
Application of analytical method to urinary excretion studies
The metabolites α-OHTRZ and 4-OHTRZ were found in urine after oral administration of the 0.25 mg triazolam tablet. The mean cumulative urinary excretion of triazolam, α-OHTRZ, and 4-OHTRZ as a function of time profiles are shown in Figure 2 . Most of the triazolam and metabolites were excreted within the first 12 h. Of the orally administered dose of triazolam, a total of 0.0015 ± 0.0006 mg was recovered in the urine, and this corresponds to 0.58 ± 0.25% on a molar basis. The cumulative urinary amount of triazolam, α-OHTRZ, and 4-OHTRZ and percentage of the dose following administration of the triazolam are summarized in Table V . Our urinary excretion patterns of α-OHTRZ and 4-OHTRZ are similar to those Tsujikawa and colleagues reported (4) . It is clear that interindividual variation existed after administration of the same amount of triazolam. Significant interindividual variation was reflected in the extraordinarily large standard deviation.
A reliable LC-MS-MS method has been developed for simultaneous determination of triazolam and its metabolites in human urine. Despite the fully validated data to demonstrate the applicability of this method, only a single MRM transition for each target compound was used, which is suitable for quantitation of analytes already known to be present in a sample. Generally, it is not considered acceptable for identification of an analyte in a sample to use a single MRM transition. Therefore, caution should be used when this method is used for qualitative identification of the target analytes in an unknown sample. In the case of triazolam, there might be some compounds that have the same precursor/product ions with triazolam when using a single MRM transition, which could lead to erroneous identification. However, simultaneous monitoring of triazolam and its two metabolites might abate this problem because those interferences must share the same metabolic pathway in human urine, which seems very unlikely to occur. 
Conclusions
The LC-MS-MS method is a simultaneous, sensitive, accurate, and selective assay for the determination of triazolam and its metabolites in human urine with a chromatographic run time less than 4 min. Also, clinical human urine samples were successfully analyzed by this method, which indicates that it could apply to analysis of urine for drug of abuse.
